July 12th 2024
“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Adjuvant Nivolumab Misses DFS End Point in Locally Advanced High-Risk RCC
January 27th 2024Treatment with nivolumab did not reach the primary endpoint of disease-free survival when compared with placebo in patients with localized renal cell carcinoma at high risk of relapse after nephrectomy in the phase 3 CheckMate 914 trial.
The Role of Registered Nurses in the Multidisciplinary Treatment of Advanced RCC
December 14th 2023Nurses play a key role in kidney cancer care by educating patients on medications, closely monitoring and managing side effects, coordinating care, providing emotional support, and serving as the first line of communication with patients about treatment concerns.
Diagnosis and Risk Stratification of Patients With RCC
November 30th 2023Dr Thomas Hutson outlines the diagnosis and staging of renal cell carcinoma, the surgical and non-surgical treatment options, and notes that while the majority of cases are potentially curable, 20-25% of patients present with or later develop metastatic disease.